Patents Examined by Alana Harris Dent
  • Patent number: 9963517
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 8, 2018
    Assignees: Genentech, Inc., University of Turku
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Patent number: 9901629
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: February 27, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 9902778
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 27, 2018
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • Patent number: 9861688
    Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 9, 2018
    Assignees: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Universitaet Duisburg-Essen
    Inventors: Dirk Schadendorf, Annette Paschen, Silke Luebcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
  • Patent number: 9815906
    Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 14, 2017
    Assignees: TSINGHUA UNIVERSITY, PROTGEN LTD.
    Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
  • Patent number: 9809815
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: November 7, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Wöll, Gabriela-Elena Oprea
  • Patent number: 9775785
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 3, 2017
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Koslowski, Stephan Fritz, Harald-Gerhard Geppert
  • Patent number: 9718886
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: August 1, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • Patent number: 9671406
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 6, 2017
    Assignee: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 9671412
    Abstract: Antibodies specific for human Beclin 1 protein phosphorylated Ser234, Ser295, Tyr229, Tyr233 or Try352 are useful in diagnosing diseases such as cancer and impaired autophagy. The invention further relates to human Beclin 1 mutated at Ser234, Ser295, Tyr229, Tyr233 or Try352 with a phospho-silencing residue and uses thereof.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: June 6, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Beth C. Levine, Richard C. Wang, Yongjie Wei
  • Patent number: 9663585
    Abstract: Monoclonal antibodies against DCLK1 and conjugates containing these monoclonal antibodies are disclosed. Methods of producing and using these monoclonal antibodies are also disclosed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 30, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Courtney Houchen, Sripathi M. Sureban, Randal May, Dongfeng Qu, Nathaniel Weygant
  • Patent number: 9657077
    Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 23, 2017
    Assignees: UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia
  • Patent number: 9644020
    Abstract: The present invention provides a human Tim-3-Ig fusion protein which can block Tim-3 signal pathway, and said Ig fusion protein comprises Tim-3 protein, human Ig fragment, and the linking sequence therebetween. In the present invention, a human Tim-3-Ig gene is obtained by an artificial synthesis process; an expression vector containing the Tim-3-Ig gene is constructed; and the prepared Ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice. The human Tim-3-Ig fusion protein prepared in the present invention can be used to treat immunological diseases caused by high expression of Tim-3.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: May 9, 2017
    Assignee: Institute of Basic Medical Science, the Academy of Military Medical Science of the Chinese PLA
    Inventors: Gencheng Han, Guojiang Chen, Xingwei Jiang, Renxi Wang, He Xiao, Chunmei Hou, Jiahui Yu, Zhi Zhao, Jiannan Feng, Yan Li, Beifen Shen
  • Patent number: 9637548
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: May 2, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 9585939
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 7, 2017
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Andrei V. Gudkov
  • Patent number: 9581598
    Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: February 28, 2017
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Pirjo Laakkonen
  • Patent number: 9579361
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: February 28, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Patent number: 9567640
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 14, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9556491
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: January 31, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9549971
    Abstract: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 24, 2017
    Assignee: GENENTECH, INC.
    Inventors: Weilan Ye, Han Lu